Oncology conferences

This EMBO | EMBL Symposium brings cancer researchers together to examine how tumours spread and resist treatment. Topics include circulating and metastasis-initiating cells, invasion, epigenetic regulation, dormancy, cellular plasticity, immune escape and the tumour microenvironment. The programme connects biological mechanisms with imaging, single-cell and spatial profiling, computational analysis and disease models. The event runs from 10 to 13 November 2026 at the EMBL Advanced Training Centre in Heidelberg, with virtual participation available. Abstract submissions are closed. On-site registration closes on 29 September; virtual registration remains available until 3 November. Registration fees and the two booking routes are listed on the organizer page.

The congress connects experimental and clinical pharmacology, from identifying therapeutic targets and testing mechanisms in preclinical models to clinical trials, access to treatment and evidence from routine care. Its programme examines synaptic and cellular communication in neurodegeneration, immunometabolism, inflammation, oncology, precision medicine and sex-aware experimental design. Sessions also address drug development, regulatory decisions, artificial intelligence and the sustainability of pharmacological research. Plenary lectures connect unmet needs in oncology to improved care and trace lysosomal calcium signalling from discovery towards clinical applications. Parallel symposia, young-investigator presentations and discussions bring together basic research and translational practice. Times are Europe/Rome (CET, UTC+1). On 25 November, parallel sessions begin at 13:30, the opening ceremony is 15:30–16:00 and the first plenary is 16:00–17:00. Morning sessions begin at 08:30 on 26–28 November. The final plenary is 11:30–12:30 on 28 November, followed by conclusions and awards until 13:00. Standard full-congress fees are EUR 500 for SIF members and EUR 300 for members under 38; academic non-members pay EUR 854, or EUR 488 if under 38, including VAT. Industry non-members pay EUR 1,159, with a higher PayPal rate. Day tickets are available. Shared-room accommodation for eligible non-tenured SIF members under 38 is subject to a waiting list after 16 June. Registration requires a separate congress-platform account; SIF website credentials do not apply.

Hosted by the American Society of Hematology, this meeting connects basic and translational blood research with clinical practice. Scientific sessions examine how genomic diagnostics, long-read sequencing and three-dimensional marrow models improve understanding of inherited disorders; how clonal selection and immune escape drive marrow failure; and how RNA regulation offers therapeutic targets in leukemia. AI-assisted flow cytometry, spatial multi-omics and epigenomic profiling link molecular mechanisms to diagnosis and risk stratification. Further sessions investigate stem-cell niches and immune control, tissue-resident T cells, iron homeostasis and erythrocyte metabolism, plasma-cell biology and treatment resistance. Structural and biophysical studies of coagulation, engineered vascular models and targeted imaging address thrombosis and fibrinolysis, including anti-PF4 disorders and safer platelet inhibition. Transplantation and cellular therapies extend into autoimmune disease. Didactic presentations, panels and questions accompany scientific, educational, oral-abstract and poster sessions. Programme times are America/Chicago (CST, UTC−6). The main meeting starts on 12 December with in-person ticketed expert sessions and poster walks at 08:00; Education/Scientific Program and oral-abstract sessions begin at 09:30. The Sunday plenary runs 14:00–16:00, Monday Education/Scientific Program sessions begin at 10:30, and Tuesday late-breaking abstracts begin at 07:30. Best of ASH ends at 13:00 on 15 December. Most sessions stream live; recordings remain available according to the purchased access tier. Friday workshops and satellite symposia are separate pre-meeting activities. Advance in-person or Real-Time virtual fees are USD 900 for active/international members, USD 1,700 for non-members, USD 175 for associate/student/resident members, USD 275 for non-member trainees and USD 800 for allied health professionals. The advance discount ends 21 October at 23:59 Pacific Time; non-member trainee advance rates continue through 1 December. Extended virtual access costs extra. Registration requires an ASH account and payment. In-person expert sessions require separate on-site tickets; trainee-only activities require the appropriate badge.

A conference connecting fundamental cancer research from molecules and cells to tissues, organs and whole organisms. Sessions cover molecular mechanisms, enabling technologies, cell behaviour, and cancer’s interactions with immunity, metabolism and its environment. Early-career and established researchers can develop interdisciplinary collaborations; poster sessions and selected lightning talks provide opportunities to present research. Abstracts close on 30 October 2026, with decisions from 13 November. Early-bird rates ended on 11 September; standard rates apply through 27 November, followed by final admission rates from 28 November. Standard student tickets cost £125, academic/clinical/not-for-profit/healthcare tickets £175 and industry tickets £250; the listed LMIC rate is £50. Programme refreshments and lunches are included.

This Keystone Symposium examines how nerves and neural activity shape cancer initiation, progression, metastasis, cognition, and treatment, with a focus on actionable therapeutic targets.

The scientific programme examines future directions in urology, including oncology, robotics, artificial intelligence, registries, reconstruction, functional urology and andrology. International and regional faculty will discuss developments in research and clinical care, alongside the ANZUNS programme. Attendance requires paid registration. Industry representatives who provide or promote urology-related products or services must participate as sponsors or exhibitors rather than register as delegates. Abstract submissions have closed. Authors must accept their offers by 6 November 2026, presenters must register by 11 December, and early-bird registration ends on 15 January 2027.

This symposium compares mechanisms of drug resistance, tolerance and persistence in bacteria, fungi and cancer. It explores how genetic change, non-genetic cellular plasticity, biochemistry and metabolism combine to let cells survive treatment. Themes include evolution under drug pressure, genome plasticity, stress responses, cellular fitness and the ecological context of drug responses. Efflux, microenvironmental effects and other extracellular contributors are considered alongside cellular states and biochemical mechanisms. By comparing systems across species, the programme aims to deepen understanding of clonal evolution and single-cell biology and inform strategies for tackling drug resilience.

The American Association for Cancer Research's flagship annual meeting, themed 'Delivering Discovery Science: The Bridge to Breakthrough Therapeutics', at the Orange County Convention Center in Orlando, Florida.